Advertisement
Advertisement

TVTX

TVTX logo

Travere Therapeutics, Inc. Common Stock

58.41
USD
Sponsored
+0.11
+0.19%
Jun 30, 12:59 UTC -4
Open

TVTX Earnings Reports

Positive Surprise Ratio

TVTX beat 17 of 42 last estimates.

40%

Next Report

Date of Next Report
Jul 30, 2026
Estimate for Q2 26 (Revenue/ EPS)
$163.56M
/
-$0.09
Implied change from Q1 26 (Revenue/ EPS)
+28.59%
/
-77.50%
Implied change from Q2 25 (Revenue/ EPS)
+42.91%
/
-35.71%

Travere Therapeutics, Inc. Common Stock earnings per share and revenue

On May 04, 2026, TVTX reported earnings of -0.40 USD per share (EPS) for Q1 26, missing the estimate of -0.27 USD, resulting in a -47.66% surprise. Revenue reached 127.20 million, compared to an expected 139.01 million, with a -8.50% difference. The market reacted with a -0.24% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 11 analysts forecast an EPS of -0.09 USD, with revenue projected to reach 163.56 million USD, implying an decrease of -77.50% EPS, and increase of 28.59% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Grace Therapeutics, Inc. Common Stock
Report Date
Jun 18, 2026 For Q4 26
Estimate
-$0.23
Actual
-$0.06
Surprise
+74.42%
FAQ
For Q1 2026, Travere Therapeutics, Inc. Common Stock reported EPS of -$0.40, missing estimates by -47.66%, and revenue of $127.20M, -8.5% below expectations.
The stock price moved down -0.24%, changed from $44.91 before the earnings release to $44.80 the day after.
The next earning report is scheduled for Jul 30, 2026.
Based on 11 analysts, Travere Therapeutics, Inc. Common Stock is expected to report EPS of -$0.09 and revenue of $163.56M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement